NCT05940532View on ClinicalTrials.gov

A Trial of Sugemalimab and Chemotherapy in Unresectable Stage III NSCLC

PHASE2RecruitingINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

January 31, 2025

Study Completion Date

December 31, 2026

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

Sugemalimab and Chemotherapy

"Chemotherapy: Paclitaxel 175mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for NSCLC; Pemetrexed 500mg/m2 D1, Carboplatin AUC=5 or DDP 75mg/m2 D1 for non-squamous NSCLC; intravenous infusion every 3 weeks, for up to four cycles.~Sugemalimab: 1200 mg by intravenous infusion every 3 weeks, for up to 2 years."

Trial Locations (1)

Unknown

RECRUITING

Hunan Cancer Hospital, Changsha

All Listed Sponsors
lead

Hunan Cancer Hospital

OTHER